Format

Send to

Choose Destination
Nat Med. 2016 May 5;22(5):472-8. doi: 10.1038/nm.4091.

A framework for understanding and targeting residual disease in oncogene-driven solid cancers.

Author information

1
Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
2
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
3
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California, USA.
4
Department of Medicine and Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Abstract

Molecular targeted therapy has the potential to dramatically improve survival in patients with cancer. However, complete and durable responses to targeted therapy are rare in individuals with advanced-stage solid cancers. Even the most effective targeted therapies generally do not induce a complete tumor response, resulting in residual disease and tumor progression that limits patient survival. We discuss the emerging need to more fully understand the molecular basis of residual disease as a prelude to designing therapeutic strategies to minimize or eliminate residual disease so that we can move from temporary to chronic control of disease, or a cure, for patients with advanced-stage solid cancers. Ultimately, we propose a shift from the current reactive paradigm of analyzing and treating acquired drug resistance to a pre-emptive paradigm of defining the mechanisms that result in residual disease, to target and limit this disease reservoir.

PMID:
27149220
PMCID:
PMC5384713
DOI:
10.1038/nm.4091
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center